lilly tirzepatide lawsuit Novo Nordisk has filed a against Eli Lilly, alleging that the company's advertising for its blockbuster GLP-1 obesity and diabetes drugs misleads consumers by using outdated clinical trial comparisons. The Danish Your GLP-1 Compound Access Could

Additional symptoms include poor balance, confusion, difficulty remembering, and depression

The primary effects of GLP-1 receptor agonists involve the gastrointestinal system: nausea, vomiting, diarrhea, and constipation are well-documented, but pharyngeal symptoms are not a recognized direct response to the drug

Seek medical review if these symptoms develop

Doctor Requirement Baseline A1C, liver function tests, and amylase monitoring are recommended

Emotional eating, binge-eating tendencies, psychiatric comorbidity, learned eating behaviour, reward sensitivity, and baseline dietary patterns may all shape how patients perceive and respond to GLP-1RA-induced changes in satiety, nausea, food preference, and hedonic evaluation

Trial populations and endpoints differ, and individual outcomes vary regardless of whether a branded or compounded formulation is used